The Chloroquine for Influenza Prevention Trial
- Registration Number
- NCT01078779
- Lead Sponsor
- National University Hospital, Singapore
- Brief Summary
A randomised controlled trial to determine the efficacy of chloroquine for the prevention of influenza
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1516
Inclusion Criteria
- Age 18 -65
- Have the ability to provide informed consent
- If a woman of child-bearing potential, willing to use contraception for the period of the trial
Exclusion Criteria
- Acute influenza-like illness at screening
- History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy of any cause, cardiac arrhythmias, or serious hepatic or renal disease
- Pregnancy or breast feeding
- Current use of medication with known serious hepatotoxic effects
- Current use of medication with known serious interaction with CQ: amiodarone, anticonvulsants, ciclosporin, digoxin, mefloquine, moxifloxacin
- Current severe depression (as indicated by current use of antidepressant medication)
- Known serious retinal disease
- Current or recent (within the past 30 days) participation in any other clinical intervention trial.
- Known G6PD deficiency
- Vaccination for influenza (seasonal or H1N1 strain) within the 3 months prior to screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Chloroquine Chloroquine -
- Primary Outcome Measures
Name Time Method Laboratory-confirmed influenza-like illness 12 weeks
- Secondary Outcome Measures
Name Time Method Serologically-confirmed influenza infection (symptomatic or asymptomatic) 12 weeks Four-fold rise in influenza antibody titre at week 12 compared to the baseline sample
Trial Locations
- Locations (1)
Investigational Medicines Unit, National University Hospital
🇸🇬Singapore, Singapore